NCT05746039View on ClinicalTrials.gov

Feasibility of Semaglutide in Advanced Lung Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

December 28, 2025

Study Completion Date

December 28, 2025

Conditions
ObesityInterstitial Lung DiseaseChronic Obstructive Pulmonary DiseaseSarcoidosis, PulmonaryPulmonary Hypertension
Interventions
DRUG

Semaglutide Pen Injector

Once weekly subcutaneous injection

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania Perelman School of Medicine, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER